UCB PHARMA SA
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 116
- Registration Number
- NCT00175890
Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1701
- Registration Number
- NCT00175903
A Study of Brivaracetam in Subjects With Partial Onset Seizures
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 157
- Registration Number
- NCT00175929
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 857
- Registration Number
- NCT00175877
- Locations
- πΊπΈ
140, Orlando, Florida, United States
π¨π±49, Santiago de Chile, Chile
πΊπΈ136, Tampa, Florida, United States
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 853
- Registration Number
- NCT00175916
- Locations
- π§πͺ
506, Brugge, Belgium
π§πͺ505, Leuven, Belgium
π¦πΉ509, Graz, Austria
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 310
- Registration Number
- NCT00160706
- Locations
- πΊπΈ
45141, Seattle, Washington, United States
πΊπΈ45022, Houston, Texas, United States
πΏπ¦39004, PORT Elisabeth, South Africa
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 729
- Registration Number
- NCT00160589
POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 200
- Registration Number
- NCT00160537
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT00160576
Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 154
- Registration Number
- NCT00160550
Β© Copyright 2024. All Rights Reserved by MedPath